Welcome to our dedicated page for Mink Therapeutics SEC filings (Ticker: INKT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
MiNK Therapeutics, Inc. filings document a clinical-stage biopharmaceutical company focused on allogeneic iNKT cell therapies, including formal disclosures about agenT-797, program updates, operating results and financing activity. Current reports have covered quarterly and annual financial results, clinical and publication-related updates, potential strategic discussions, and an at-the-market common stock sales agreement registered under a shelf registration statement.
The company’s proxy and governance filings disclose annual meeting matters, director elections, auditor ratification, board appointments, officer designations and compensation-related items. Other filings describe its Nasdaq-listed common stock, equity incentive plan activity, intercompany services arrangements with Agenus for finance functions, and risk-sensitive updates related to clinical development, capital needs and public-company governance.
MiNK Therapeutics director Robert Peter Kadlec was granted a stock option to buy 3,225 shares of common stock at an exercise price of $15.36 per share on 09/09/2025. The option is an award that vests in full on the one-year anniversary of the grant date if Mr. Kadlec remains on the board and expires on 09/09/2035. The Form 4 was filed for the reporting person identified at a New York address and signed by an attorney-in-fact on 09/11/2025. No cash proceeds were reported at the time of filing.
MiNK Therapeutics director Peter Behner was granted a stock option on 09/09/2025 to buy 3,225 shares of common stock at an exercise price of $15.36 per share. The option was reported on Form 4 filed 09/11/2025 and is exercisable through 09/09/2035. The option vests in full on the one-year anniversary of the grant date provided Mr. Behner continues to serve on the company's board through that date. Following the grant, Mr. Behner beneficially owns 3,225 shares via this option, held directly.
MiNK Therapeutics insider grant to director Brian Corvese: The filing reports a stock option grant awarding the Reporting Person the right to buy 3,225 shares of MiNK Therapeutics common stock at an exercise price of $15.36 per share. The transaction date is listed as 09/09/2025 and the option shows an expiration date of 09/09/2035 in the table. The form states the option "vests in full on the one-year anniversary of the date of grant" provided the reporting person continues to serve on the company’s board through that date. The Form 4 was signed by an attorney-in-fact on behalf of the reporting person on 09/11/2025.
MiNK Therapeutics director Ulf Wiinberg received a grant of stock options on 09/09/2025 allowing purchase of 3,225 shares of common stock at an exercise price of $15.36 per share. The Form 4 shows the options were acquired (transaction code A) and the reporting person beneficially owns 3,225 shares following the transaction. The option term includes an expiration date shown as 09/09/2035 on the filing, and the filing discloses the option vests in full on the one‑year anniversary of the grant if the director continues to serve on the board through that date. The reporting person is identified as a director and the Form 4 was signed by an attorney‑in‑fact.
MiNK Therapeutics director Barbara Ryan received a stock option grant on 09/09/2025. The option gives the right to buy 3,225 shares of common stock at an exercise price of $15.36 per share, is exercisable beginning 09/09/2025, and expires 09/09/2035. The option vests in full on the one-year anniversary of the grant date if the reporting person continues to serve on the board. The Form 4 was filed by one reporting person and signed by an attorney-in-fact on 09/11/2025.
Ulf Wiinberg, a director of MiNK Therapeutics, Inc. (INKT), reported a grant and his current holdings. On 09/02/2025 Mr. Wiinberg was granted 1,011 restricted stock units (RSUs) received in lieu of cash board and committee retainers; the RSUs vest one month from the grant date and are valued at $13.86 per share on the filing. Following the grant he beneficially owns 18,971 shares directly and 27,830 shares indirectly held in an irrevocable trust for his family.
MiNK Therapeutics director Robert Peter Kadlec was granted 975 restricted stock units (RSUs) as board and committee compensation on 09/02/2025. The RSUs, received in lieu of cash retainers, represent a contingent right to one share of common stock per RSU and will vest one month from the grant date. Following the award, the reporting person beneficially owns 17,908 shares. The transaction is reported on Form 4 for ticker INKT and was signed by an attorney-in-fact on 09/03/2025.
MiNK Therapeutics director Barbara Ryan received 1,281 restricted stock units (RSUs) as board and committee compensation on 09/02/2025. Each RSU converts to one share of common stock; the reported RSUs were granted in lieu of cash retainers and will vest one month from the grant date. Following the grant, Ms. Ryan beneficially owns 20,805 shares of common stock. The transaction price recorded for the RSUs is $13.86 per share (used for reporting purposes).
Brian Corvese, a director of MiNK Therapeutics, Inc. (INKT), was granted 1,290 restricted stock units (RSUs) on 09/02/2025 as board and committee compensation in lieu of cash. Each RSU represents a contingent right to receive one share of common stock and the grant price shown on the form is $13.86 per share. After the grant, the reporting person beneficially owns 48,441 shares. The RSUs are scheduled to vest one month from the grant date. The Form 4 was signed by an attorney-in-fact on 09/03/2025.
MiNK Therapeutics director Peter Behner received 1,173 restricted stock units (RSUs) on 09/02/2025, granted in lieu of cash board and committee retainers. Each RSU represents a contingent right to one share of common stock and will vest one month from the grant date.
After the grant, Mr. Behner beneficially owns 18,649 shares of MiNK common stock on a direct basis. The reported per-share value associated with the grant is $13.86. The Form 4 was submitted to disclose this change in beneficial ownership.